Log in
  • PO Box 450 Mawson ACT, 2607 Australia

  • 02 6260 4022

CMA's Response to TGA's New Ashwagandha (Withania somnifera) Gastrointestinal / Liver Reports

23 Feb 2024 12:19 PM | Anonymous member (Administrator)

The Therapeutic Goods Administration (TGA) has published a safety advisory regarding emerging reports of gastrointestinal symptoms associated with the ingredient Withania somnifera (also known as Ashwagandha). Some consumers experience mild gastrointestinal symptoms to herbal ingredients including Withania. The TGA safety advisory reports that Withania somnifera has caused more severe gastrointestinal symptoms such as nausea, vomiting or diarrhoea in some cases and in very rare cases, possible liver injury. 

To read more, please click here.

Copyright © 2019 Complementary Medicines Australia. All rights reserved.

Powered by Wild Apricot Membership Software